Ureteral colic is a common reason for patients to seek medical care. Alpha‐blockers
are commonly used to improve stone passage through so‐called medical expulsive therapy
(MET), but their effectiveness remains controversial. This is an update of a 2014
Cochrane review; since that time, several large randomised controlled trials (RCTs)
have been reported, making this update relevant. To assess effects of alpha‐blockers
compared with standard therapy for ureteral stones 1 cm or smaller confirmed by imaging
in adult patients presenting with symptoms of ureteral stone disease. On 18 November
2017, we searched CENTRAL, MEDLINE Ovid, and Embase. We also searched ClinicalTrials.gov
and the WHO Portal/ICTRP to identify all published/unpublished and ongoing trials.
We checked all references of included and review articles and conference proceedings
for articles relevant to this review. We sent letters to investigators to request
information about unpublished or incomplete studies. We included RCTs of ureteral
stone passage in adult patients that compared alpha‐blockers versus standard therapy.
Two review authors screened studies for inclusion and extracted data using standard
methodological procedures. We performed meta‐analysis using a random‐effects model.
Primary outcomes were stone clearance and major adverse events; secondary outcomes
were stone expulsion time, number of pain episodes, use of diclofenac, hospitalisation,
and surgical intervention. We assessed the quality of evidence on a per‐outcome basis
using the GRADE approach. We included 67 studies with 10,509 participants overall.
Of these, 15 studies with 5787 participants used a placebo. Stone clearance: Based
on the overall analysis, treatment with an alpha‐blocker may result in a large increase
in stone clearance (risk ratio (RR) 1.45, 95% confidence interval (CI) 1.36 to 1.55;
low‐quality evidence). A subset of higher‐quality, placebo‐controlled trials suggest
that the likely effect is probably smaller (RR 1.16, 95% CI 1.07 to 1.25; moderate‐quality
evidence), corresponding to 116 more (95% CI 51 more to 182 more) stone clearances
per 1000 participants. Major adverse events: Based on the overall analysis, treatment
with an alpha‐blocker may have little effect on major adverse events (RR 1.25, 95%
CI 0.80 to 1.96; low‐quality evidence). A subset of higher‐quality, placebo‐controlled
trials suggest that alpha‐blockers likely increase the risk of major adverse events
slightly (RR 2.09, 95% CI 1.13 to 3.86), corresponding to 29 more (95% CI 3 more to
75 more) major adverse events per 1000 participants. Patients treated with alpha‐blockers
may experience shorter stone expulsion times (mean difference (MD) ‐3.40 days, 95%
CI ‐4.17 to ‐2.63; low‐quality evidence), may use less diclofenac (MD ‐82.41, 95%
CI ‐122.51 to ‐42.31; low‐quality evidence), and likely require fewer hospitalisations
(RR 0.51, 95% CI 0.34 to 0.77; moderate‐quality evidence), corresponding to 69 fewer
hospitalisations (95% CI 93 fewer to 32 fewer) per 1000 participants. Meanwhile, the
need for surgical intervention appears similar (RR 0.74, 95% CI 0.53 to 1.02; low‐quality
evidence), corresponding to 28 fewer surgical interventions (95% CI 51 fewer to 2
more) per 1000 participants. A predefined subgroup analysis (test for subgroup differences;
P = 0.002) suggests that effects of alpha‐blockers may vary with stone size, with
RR of 1.06 (95% CI 0.98 to 1.15; P = 0.16; I² = 62%) for stones 5 mm or smaller versus
1.45 (95% CI 1.22 to 1.72; P < 0.0001; I² = 59%) for stones larger than 5 mm. We found
no evidence suggesting possible subgroup effects based on stone location or alpha‐blocker
type. For patients with ureteral stones, alpha‐blockers likely increase stone clearance
but probably also slightly increase the risk of major adverse events. Subgroup analyses
suggest that alpha‐blockers may be less effective for smaller (5 mm or smaller) than
for larger stones (greater than 5 mm). Review question Does medical treatment with
alpha‐blockers improve the outcomes of patients with stones stuck in their ureter?
Background Stones stuck in the ureter, which is the tube that transports urine from
the kidney to the bladder, often cause pain and make people see a doctor. Depending
on which part of the ureter the stone is stuck in and the size of the stone, it will
often pass into the bladder on its own over the course of weeks. If the stone does
not come out by itself, people often need to have procedures done to remove the stone.
Alpha‐blockers are medications that relax muscles in the urinary tract and may make
the stone pass into the bladder faster. However, they can cause unwanted effects.
We updated an existing Cochrane Review from 2014 to look into the effects of alpha‐blockers.
Study characteristics Based on our latest search of the literature from November 2017,
we included 64 studies with 10,509 participants. Of these, 15 studies compared alpha‐blockers
with placebo with 5787 participants. A placebo is a pill that looks and tastes exactly
like the real medication, so participants did not know what they were getting. These
were the higher‐quality studies, which we trusted more. Key results Based on the subset
of higher‐quality studies that used a placebo, alpha‐blockers likely resulted in more
people passing their stones. However, these patients are likely to experience slightly
more serious unwanted effects of this medication. People taking alpha‐blockers may
pass their stones in a shorter time, may use less diclofenac (which is a type of pain
medication), and are likely to be admitted to the hospital less often. Meanwhile,
the need for surgery for their stones was similar. Upon completing additional analyses,
we found that effects of alpha‐blockers may be different in people with small (5 mm
or smaller) versus larger (larger than 5 mm) stones. It appears that this medication
works better in people with larger stones. We could find no difference in how well
alpha‐blockers work, no matter where in the ureter the stone is stuck or what type
of alpha‐blocker is used. Authors' conclusions For patients with stones stuck in the
ureter, alpha‐blockers likely make passing the stone easier but cause slightly more
unwanted effects. It appears that alpha‐blockers work better in people with larger
(greater than 5 mm) rather than smaller (5 mm or smaller) stones. Quality of the evidence
The quality of the evidence for most outcomes was moderate or low, meaning that we
have moderate or low confidence in most of the reported results.